Gilead's Kite To Buy Tmunity, Enhancing CAR-T Pipeline And Manufacturing
Kite CEO Christie Shaw said Tmunity brings three advantages: armored CAR-Ts, manufacturing technology and an ongoing research deal with the University of Pennsylvania.
You may also be interested in...
Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III
Excluding sales declines due to Veklury, Gilead said its year-over-year sales grew 15% in the first quarter, with HIV drug Biktarvy serving as the biggest driver.
Deal Watch: Merck KGaA Teams Up With Mersana On STING Agonist ADCs
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Deal With Arcellx Gives Gilead New Beachhead In Multiple Myeloma
Deal Snapshot: Months after terminating its Phase I BCMA-targeting CAR-T program and on the eve of ASH, Gilead’s Kite announced a deal with Arcellx for a CAR-T that has already shown promising data.